Novartis loses global development head to Gates Foundation

pharmafile | September 14, 2011 | News story | Research and Development Bill and Melinda Gates Foundation, Novartis, appointment 

Novartis’ global head of development Trevor Mundel is to leave the company and take a senior position at The Bill and Melinda Gates Foundation.

He will remain with Novartis until 1 December, after which he will take up the role of executive director of the Foundation’s Global Health Program.

At Novartis Mundel’s responsibilities included overseeing the development of drug candidates provided by the Novartis Institutes for BioMedical Research (NIBR) or the company’s licensing partners.

Prior to joining Novartis, he worked for Warner Lambert and Pfizer in senior clinical development roles, including director in central nervous system clinical development and as head of  experimental Medicine, respectively.

Advertisement

Novartis said it would name Mundel’s successor shortly.

Dominic Tyer

Related Content

Scotland starts newborn screening for SMA

As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

The Gateway to Local Adoption Series

Latest content